Target intelligence / Profile preview

HLA class II histocompatibility antigen, DQ beta 1 chain (HLA-DQB1*05:02) (HLA-DQB1*05:02)

Target
HLA-DQB1*05:02
Molecular classification
MHC class II receptor, HLA-DQ complex, Receptor
01

Overview

HLA-DQB1*05:02 is a specific allele of the Human Leukocyte Antigen (HLA) class II beta chain, which forms a heterodimer with an alpha chain to create the HLA-DQ protein complex (UniProt: P01920). This complex is expressed on the surface of professional antigen-presenting cells, where its primary biological function is to bind exogenous peptides within its peptide-binding groove and present them to CD4+ T-helper cells (IMGT/HLA Database). This interaction is a critical step in the initiation of the adaptive immune response. HLA-DQB1*05:02 is highly significant in clinical medicine due to its strong genetic association with Muscle-Specific Kinase (MuSK) antibody-positive Myasthenia Gravis, an autoimmune neuromuscular disorder (Niks et al., 2007, PMID: 17606768). In these patients, the HLA-DQB1*05:02 molecule is thought to preferentially present MuSK-derived peptides, leading to the loss of self-tolerance and the production of pathogenic IgG4 autoantibodies (Stathopoulos et al., 2017, PMID: 28100595). While not a traditional target for small molecule inhibitors, the peptide-binding groove of this specific HLA allele represents a focal point for developing selective immunotherapies, such as peptide-based decoys or TCR-like antibodies, aimed at blocking the presentation of autoantigens without causing broad immunosuppression (Zisimopoulou et al., 2017). Additionally, this allele has been linked to other autoimmune conditions, such as bullous pemphigoid, highlighting its role in aberrant immune recognition (Fang et al., 2018). Therapeutic challenges include the high polymorphism of HLA genes and the need for extreme specificity to avoid off-target immune suppression.

Other names
MHC class II antigen DQB1*05:02HLA-DQ5.2HLA-DQB1*0502Major histocompatibility complex, class II, DQ beta 1
02

Mechanism of action

Presentation of autoantigenic peptides to CD4+ T cells; potential target for competitive peptide inhibition

03

Biological functions

Antigen presentationImmune responseT-cell activation
04

Disease associations

Myasthenia gravis (MuSK-antibody positive)Bullous pemphigoidAutoimmune disease
05

Safety considerations

Allele-specific targeting challengesPotential for broad immunosuppressionRisk of cross-reactivity with other HLA alleles
06

Interacting drugs

None currently approved
07

Biomarkers

HLA-DQB1*05:02 genotypeAnti-MuSK antibodies

Beyond the preview

Go deeper on HLA class II histocompatibility antigen, DQ beta 1 chain (HLA-DQB1*05:02) (HLA-DQB1*05:02).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLA class II histocompatibility antigen, DQ beta 1 chain (HLA-DQB1*05:02) (HLA-DQB1*05:02).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call